Kamada Ltd. (KMDA) 3.71 $KMDA
Kamada's Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform
GlobeNewswire - Wed May 25, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, and myTomorrows, a provider of services to patients and physicians in need of diagnostic tests and drugs in development, today announced a collaboration to provide early access throughout Europe to Kamada's proprietary, highly-purified, liquid form of Alpha-1 Antitrypsin (AAT) to treat bone marrow transplant patients who develop steroid refractory Graft-Versus-Host Disease (GvHD).
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Kamada Reports 2016 First Quarter Financial Results
BusinessWire - Mon May 09, 5:30AM CDT
--Conference call begins at 8:30 a.m. Eastern time today
KMDA: 3.71 (-0.01)
Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern Time
BusinessWire - Wed May 04, 7:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the first quarter ended March 31, 2016 prior to the open of the U.S. financial markets on Monday, May 9, 2016.
KMDA: 3.71 (-0.01)
Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta
BusinessWire - Mon May 02, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces receipt of two milestone payments as a result of achieving certain regulatory and sales milestones under the strategic agreements with Chiesi Farmaceutici S.p.A. and Baxalta Incorporated (NYSE: BXLT).
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
BusinessWire - Wed Apr 06, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces in the initiation of a Phase 2 clinical trial with its proprietary Alpha-1 Antitrypsin (AAT) for the prevention of lung transplant rejection. The study is being conducted in collaboration with Baxalta Incorporated (NYSE: BXLT), which has distribution rights to the Company's intravenous (IV) AAT for all indications in the U.S., Canada, Australia and New Zealand.
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
BusinessWire - Mon Mar 28, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the Company's proprietary, inhaled alpha-1 antitrypsin (AAT) therapy as a treatment for AAT deficiency (AATD). The filing was validated by the EMA.
KMDA: 3.71 (-0.01)
What's in Store for TrovaGene (TROV) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:00AM CST
TrovaGene Inc. (TROV) is scheduled to report fourth-quarter 2015 earnings results on Mar 10.
TROV: 4.51 (-0.37), KMDA: 3.71 (-0.01), AMGN: 155.42 (-1.36), MDXG: 7.91 (-0.07)
Kamada to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
BusinessWire - Fri Feb 05, 7:56AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the Company will participate at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City. Amir London, the Company's Chief Executive Officer, will present a corporate overview on February 11th from 12:30PM to 12:55PM.
KMDA: 3.71 (-0.01)
New Strong Buy Stocks for February 4th
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
CPTA: 13.91 (-0.09), NPTN: 8.90 (-0.15), KMDA: 3.71 (-0.01), CASY: 118.76 (-0.56), HRC: 50.87 (-0.35)
Kamada Reports 2015 Fourth Quarter and Full Year Financial Results
BusinessWire - Tue Feb 02, 6:17AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports financial results for the three and 12 months ended December 31, 2015.
KMDA: 3.71 (-0.01)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 10.90 (-0.12), VRTX: 92.15 (-0.34), PFE: 35.17 (-0.14), GSK: 40.91 (-1.15), CNCE: 12.76 (-0.20), GLPG: 55.55 (-1.33), CYCC: 6.04 (-0.05), PTI: 19.36 (+0.10), SHPG: 177.92 (-6.03), PULM: 2.32 (-0.15), MRK: 56.82 (-0.36), NVLS: 4.37 (-0.07), PTCT: 7.47 (-0.07), KMDA: 3.71 (-0.01), AKTX: 15.00 (-0.41), NVS: 79.05 (-1.46)
Kamada to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on February 2, 2016 at 8:30 am Eastern time
BusinessWire - Wed Jan 27, 9:41AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and twelve months ended December 31, 2015 prior to the open of the U.S. stock market open on Tuesday, February 2, 2016.
KMDA: 3.71 (-0.01)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 10.90 (-0.12), CYCC: 6.04 (-0.05), HZNP: 17.86 (-0.67), KMDA: 3.71 (-0.01), GSK: 40.91 (-1.15), AKTX: 15.00 (-0.41), APHB: 1.72 (-0.03), CNCE: 12.76 (-0.20), GLPG: 55.55 (-1.33)
Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease
BusinessWire - Wed Jan 06, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports further positive interim results from a Phase 1/2 clinical trial of its proprietary alpha-1 antitrypsin (AAT) to treat steroid-refractory Graft Versus Host Disease (GvHD) which is being conducted in collaboration with Baxalta US, Inc. (NYSE: BXLT) and the Fred Hutchinson Cancer Research Center in Seattle.
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Bronchiectasis - Pipeline Review 2015
M2 - Wed Jan 06, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/zh8r63/bronchiectasis) has announced the addition of the "Bronchiectasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Bronchiectasis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Alitair Pharmaceuticals, Inc. - Bayer AG - Grifols, S.A. - Kamada Ltd. - Nostrum Pharmaceuticals, LLC - Pulmatrix, Inc. - Recipharm AB - Savara Inc. - Serendex Pharmaceuticals A/S - Therabron Therapeutics, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/zh...chiectasis
VRTX: 92.15 (-0.34), PULM: 2.32 (-0.15), KMDA: 3.71 (-0.01)
Kamada (KMDA) Reports Encouraging Data on Rabies Drug
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 3:40PM CST
Kamada Ltd. (KMDA) reported encouraging data from a pivotal phase II/III study on its human rabies immune globulin therapy as a post-exposure treatment for rabies.
ACHN: 9.78 (+0.05), HZNP: 17.86 (-0.67), KMDA: 3.71 (-0.01), CORT: 5.40 (-0.07)
New Strong Sell Stocks for December 23rd
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
EVHC: 27.32 (-0.48), KRA: 27.46 (-0.33), KMDA: 3.71 (-0.01), GPS: 18.83 (-0.48), CMO: 9.82 (-0.03)
Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment
BusinessWire - Wed Dec 23, 5:00AM CST
--Plans to file a BLA with the FDA in mid-2016
KMDA: 3.71 (-0.01)
Evogene Appoints Eyal Leibovitz as Chief Financial Officer
GlobeNewswire - Tue Dec 22, 6:05AM CST
Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, today announced the appointment of Eyal Leibovitz as Chief Financial Officer. Mr. Leibovitz is joining the Company effective January 1, 2016 and will replace Sigal Fattal who has been with the Company since June 2012 and will remain until January 31, 2016 to ensure a smooth transition. Ms. Fattal will continue to support the Company after her departure and until April 2016. Mr. Leibovitz will report to Ofer Haviv, Evogene's President and Chief Executive Officer, and will have executive responsibility for all corporate functions of the company.
EVGN: 6.74 (-0.06), HLIT: 2.83 (-0.05), KMDA: 3.71 (-0.01)
Kamada's Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform
GlobeNewswire - Wed May 25, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, and myTomorrows, a provider of services to patients and physicians in need of diagnostic tests and drugs in development, today announced a collaboration to provide early access throughout Europe to Kamada's proprietary, highly-purified, liquid form of Alpha-1 Antitrypsin (AAT) to treat bone marrow transplant patients who develop steroid refractory Graft-Versus-Host Disease (GvHD).
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Kamada Reports 2016 First Quarter Financial Results
BusinessWire - Mon May 09, 5:30AM CDT
--Conference call begins at 8:30 a.m. Eastern time today
KMDA: 3.71 (-0.01)
Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern Time
BusinessWire - Wed May 04, 7:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the first quarter ended March 31, 2016 prior to the open of the U.S. financial markets on Monday, May 9, 2016.
KMDA: 3.71 (-0.01)
Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta
BusinessWire - Mon May 02, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces receipt of two milestone payments as a result of achieving certain regulatory and sales milestones under the strategic agreements with Chiesi Farmaceutici S.p.A. and Baxalta Incorporated (NYSE: BXLT).
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
BusinessWire - Wed Apr 06, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces in the initiation of a Phase 2 clinical trial with its proprietary Alpha-1 Antitrypsin (AAT) for the prevention of lung transplant rejection. The study is being conducted in collaboration with Baxalta Incorporated (NYSE: BXLT), which has distribution rights to the Company's intravenous (IV) AAT for all indications in the U.S., Canada, Australia and New Zealand.
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
BusinessWire - Mon Mar 28, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the Company's proprietary, inhaled alpha-1 antitrypsin (AAT) therapy as a treatment for AAT deficiency (AATD). The filing was validated by the EMA.
KMDA: 3.71 (-0.01)
What's in Store for TrovaGene (TROV) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:00AM CST
TrovaGene Inc. (TROV) is scheduled to report fourth-quarter 2015 earnings results on Mar 10.
TROV: 4.51 (-0.37), KMDA: 3.71 (-0.01), AMGN: 155.42 (-1.36), MDXG: 7.91 (-0.07)
Kamada to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
BusinessWire - Fri Feb 05, 7:56AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the Company will participate at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City. Amir London, the Company's Chief Executive Officer, will present a corporate overview on February 11th from 12:30PM to 12:55PM.
KMDA: 3.71 (-0.01)
New Strong Buy Stocks for February 4th
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
CPTA: 13.91 (-0.09), NPTN: 8.90 (-0.15), KMDA: 3.71 (-0.01), CASY: 118.76 (-0.56), HRC: 50.87 (-0.35)
Kamada Reports 2015 Fourth Quarter and Full Year Financial Results
BusinessWire - Tue Feb 02, 6:17AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports financial results for the three and 12 months ended December 31, 2015.
KMDA: 3.71 (-0.01)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 10.90 (-0.12), VRTX: 92.15 (-0.34), PFE: 35.17 (-0.14), GSK: 40.91 (-1.15), CNCE: 12.76 (-0.20), GLPG: 55.55 (-1.33), CYCC: 6.04 (-0.05), PTI: 19.36 (+0.10), SHPG: 177.92 (-6.03), PULM: 2.32 (-0.15), MRK: 56.82 (-0.36), NVLS: 4.37 (-0.07), PTCT: 7.47 (-0.07), KMDA: 3.71 (-0.01), AKTX: 15.00 (-0.41), NVS: 79.05 (-1.46)
Kamada to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on February 2, 2016 at 8:30 am Eastern time
BusinessWire - Wed Jan 27, 9:41AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and twelve months ended December 31, 2015 prior to the open of the U.S. stock market open on Tuesday, February 2, 2016.
KMDA: 3.71 (-0.01)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 10.90 (-0.12), CYCC: 6.04 (-0.05), HZNP: 17.86 (-0.67), KMDA: 3.71 (-0.01), GSK: 40.91 (-1.15), AKTX: 15.00 (-0.41), APHB: 1.72 (-0.03), CNCE: 12.76 (-0.20), GLPG: 55.55 (-1.33)
Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease
BusinessWire - Wed Jan 06, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports further positive interim results from a Phase 1/2 clinical trial of its proprietary alpha-1 antitrypsin (AAT) to treat steroid-refractory Graft Versus Host Disease (GvHD) which is being conducted in collaboration with Baxalta US, Inc. (NYSE: BXLT) and the Fred Hutchinson Cancer Research Center in Seattle.
KMDA: 3.71 (-0.01), BXLT: 46.02 (-0.18)
Bronchiectasis - Pipeline Review 2015
M2 - Wed Jan 06, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/zh8r63/bronchiectasis) has announced the addition of the "Bronchiectasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Bronchiectasis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Alitair Pharmaceuticals, Inc. - Bayer AG - Grifols, S.A. - Kamada Ltd. - Nostrum Pharmaceuticals, LLC - Pulmatrix, Inc. - Recipharm AB - Savara Inc. - Serendex Pharmaceuticals A/S - Therabron Therapeutics, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/zh...chiectasis
VRTX: 92.15 (-0.34), PULM: 2.32 (-0.15), KMDA: 3.71 (-0.01)
Kamada (KMDA) Reports Encouraging Data on Rabies Drug
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 3:40PM CST
Kamada Ltd. (KMDA) reported encouraging data from a pivotal phase II/III study on its human rabies immune globulin therapy as a post-exposure treatment for rabies.
ACHN: 9.78 (+0.05), HZNP: 17.86 (-0.67), KMDA: 3.71 (-0.01), CORT: 5.40 (-0.07)
New Strong Sell Stocks for December 23rd
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
EVHC: 27.32 (-0.48), KRA: 27.46 (-0.33), KMDA: 3.71 (-0.01), GPS: 18.83 (-0.48), CMO: 9.82 (-0.03)
Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment
BusinessWire - Wed Dec 23, 5:00AM CST
--Plans to file a BLA with the FDA in mid-2016
KMDA: 3.71 (-0.01)
Evogene Appoints Eyal Leibovitz as Chief Financial Officer
GlobeNewswire - Tue Dec 22, 6:05AM CST
Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, today announced the appointment of Eyal Leibovitz as Chief Financial Officer. Mr. Leibovitz is joining the Company effective January 1, 2016 and will replace Sigal Fattal who has been with the Company since June 2012 and will remain until January 31, 2016 to ensure a smooth transition. Ms. Fattal will continue to support the Company after her departure and until April 2016. Mr. Leibovitz will report to Ofer Haviv, Evogene's President and Chief Executive Officer, and will have executive responsibility for all corporate functions of the company.
EVGN: 6.74 (-0.06), HLIT: 2.83 (-0.05), KMDA: 3.71 (-0.01)
